Snapshot from Aug 03, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Compass Therapeutics ESMO abstract acceptance
Business clinical trial update

Compass Therapeutics ESMO abstract acceptance

Analysis based on 7 articles · First reported Jul 17, 2026 · Last updated Jul 17, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The news is a positive milestone for MiNK Therapeutics, potentially increasing investor attention ahead of the ESMO presentation. However, the impact is limited as it is a conference presentation acceptance, not final data.

Biotechnology Pharmaceuticals
Event Summary

MiNK Therapeutics announced that its abstract on the Phase 2/3 COMPANION-002 trial of tovecimig plus paclitaxel in advanced biliary tract cancer has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will be given by Dr. Nilofer Azad of Johns Hopkins University.

Key Actions
50 MiNK Therapeutics announced abstract acceptance
Entities Involved
stock
MiNK Therapeutics
MiNK Therapeutics is the company whose abstract was accepted for an oral presentation at ESMO, a positive development for its pipeline.
Importance 100.0 Sentiment 10.0
per
Nilofer Azad
Dr. Nilofer Azad is the presenter of the abstract, lending credibility as a Johns Hopkins oncologist.
Importance 30.0 Sentiment 0.0
ngo
European Society for Medical Oncology
ESMO is the conference hosting the presentation, providing a venue for Compass to present its data.
Importance 20.0 Sentiment 0.0
priv
Sidney Kimmel Cancer Center
Sidney Kimmel Cancer Center is the specific institution of the presenter, part of Johns Hopkins.
Importance 10.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The SEC is mentioned in forward-looking statements as the regulator where Compass files reports.
Importance 5.0 Sentiment 0.0
Relationships
MiNK Therapeutics related ↔ United States — United States Securities and Exchange Commission
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.